Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Br J Pharmacol
2013 Nov 01;1705:1053-63. doi: 10.1111/bph.12343.
Show Gene links
Show Anatomy links
Reversible inhibition of the glycine transporter GlyT2 circumvents acute toxicity while preserving efficacy in the treatment of pain.
Mingorance-Le Meur A, Ghisdal P, Mullier B, De Ron P, Downey P, Van Der Perren C, Declercq V, Cornelis S, Famelart M, Van Asperen J, Jnoff E, Courade JP.
???displayArticle.abstract???
Available medications for chronic pain provide only partial relief and often cause unacceptable side effects. There is therefore a need for novel molecular targets to develop new therapeutics with improved efficacy and tolerability. Despite encouraging efficacy data in rodents with inhibitors of the neuronal glycine transporter-2 (GlyT2), there are also some reports of toxicity and their development was discontinued. In order to clarify the possibility of targeting GlyT2 for the treatment of pain, we have used an integrated approach comprising in vitro pharmacology, selectivity, bioavailability, in vivo efficacy and safety assessment to analyse the properties and efficacy of ALX-1393 and Org-25543, the two published GlyT2 inhibitors from which in vivo data are available. We report that these compounds have a different set of undesirable properties that limit their usefulness as pharmacological tools. Importantly, we discover that inhibitors of GlyT2 can exert an apparent reversible or irreversible inhibition of the transporter and describe a new class of reversible GlyT2 inhibitors that preserves efficacy while avoiding acute toxicity. Our pharmacological comparison of two closely related GlyT2 inhibitors with different modes of inhibition provides important insights into their safety and efficacy profiles, uncovering that in the presence of a GlyT2 mechanism-based toxicity, reversible inhibitors might allow a tolerable balance between efficacy and toxicity. These findings shed light into the drawbacks associated with the early GlyT2 inhibitors and describe a new mechanism that might serve as the starting point for new drug development.
Alexander,
Guide to Receptors and Channels (GRAC), 5th edition.
2011, Pubmed
Alexander,
Guide to Receptors and Channels (GRAC), 5th edition.
2011,
Pubmed Aubrey,
Molecular basis for proton regulation of glycine transport by glycine transporter subtype 1b.
2000,
Pubmed
,
Xenbase Basbaum,
Cellular and molecular mechanisms of pain.
2009,
Pubmed Bunimov,
Cyclooxygenase inhibitors: instrumental drugs to understand cardiovascular homeostasis and arterial thrombosis.
2008,
Pubmed Caulfield,
The first potent and selective inhibitors of the glycine transporter type 2.
2001,
Pubmed Copeland,
Drug-target residence time and its implications for lead optimization.
2006,
Pubmed Dohi,
Glycine transporter inhibitors as a novel drug discovery strategy for neuropathic pain.
2009,
Pubmed Dubuisson,
The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats.
1977,
Pubmed Edington,
Extracellular loops 2 and 4 of GLYT2 are required for N-arachidonylglycine inhibition of glycine transport.
2009,
Pubmed
,
Xenbase Eulenburg,
Glycine transporters: essential regulators of neurotransmission.
2005,
Pubmed Gomeza,
Deletion of the mouse glycine transporter 2 results in a hyperekplexia phenotype and postnatal lethality.
2003,
Pubmed Haranishi,
The antinociceptive effect of intrathecal administration of glycine transporter-2 inhibitor ALX1393 in a rat acute pain model.
2010,
Pubmed Harsing,
Glycine transporter type-1 and its inhibitors.
2006,
Pubmed Hermanns,
Differential effects of spinally applied glycine transporter inhibitors on nociception in a rat model of neuropathic pain.
2008,
Pubmed Huang,
Long-term intrathecal administration of glycine prevents mechanical hyperalgesia in a rat model of neuropathic pain.
2000,
Pubmed Institute of Medicine (US) Committee on Advancing Pain Research, Care, and
Education,
2011,
Pubmed Irwin,
Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse.
1968,
Pubmed Javitt,
Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification.
2009,
Pubmed Ju,
Zn2+ inhibits glycine transport by glycine transporter subtype 1b.
2004,
Pubmed
,
Xenbase Jursky,
Localization of glycine neurotransmitter transporter (GLYT2) reveals correlation with the distribution of glycine receptor.
1995,
Pubmed Kilkenny,
Animal research: reporting in vivo experiments: the ARRIVE guidelines.
2010,
Pubmed Latremoliere,
Central sensitization: a generator of pain hypersensitivity by central neural plasticity.
2009,
Pubmed Lindsley,
GlyT1 - Up from the Ashes. The importance of not condemning a mechanism based on a single chemotype.
2010,
Pubmed McGrath,
Guidelines for reporting experiments involving animals: the ARRIVE guidelines.
2010,
Pubmed Mezler,
Inhibitors of GlyT1 affect glycine transport via discrete binding sites.
2008,
Pubmed
,
Xenbase Morita,
Spinal antiallodynia action of glycine transporter inhibitors in neuropathic pain models in mice.
2008,
Pubmed Rees,
Mutations in the gene encoding GlyT2 (SLC6A5) define a presynaptic component of human startle disease.
2006,
Pubmed
,
Xenbase Riederer,
MAO-inhibitors in Parkinson's Disease.
2011,
Pubmed Rousseau,
The glycine transporter GlyT2 controls the dynamics of synaptic vesicle refilling in inhibitory spinal cord neurons.
2008,
Pubmed Saddi,
The formalin test in the mouse: a parametric analysis of scoring properties.
2000,
Pubmed Scholz,
Can we conquer pain?
2002,
Pubmed Singh,
The resurgence of covalent drugs.
2011,
Pubmed Succar,
Actions of N-arachidonyl-glycine in a rat inflammatory pain model.
2007,
Pubmed Tanabe,
Glycine transporter inhibitors as a potential therapeutic strategy for chronic pain with memory impairment.
2008,
Pubmed Tjølsen,
The formalin test: an evaluation of the method.
1992,
Pubmed Vuong,
Actions of N-arachidonyl-glycine in a rat neuropathic pain model.
2008,
Pubmed Wiles,
N-Arachidonyl-glycine inhibits the glycine transporter, GLYT2a.
2006,
Pubmed
,
Xenbase Woolf,
Evidence for a central component of post-injury pain hypersensitivity.
,
Pubmed Xu,
Inhibitors of GlyT1 and GlyT2 differentially modulate inhibitory transmission.
2005,
Pubmed Zafra,
Glycine transporters are differentially expressed among CNS cells.
1995,
Pubmed Zafra,
Glycine transporters and synaptic function.
2008,
Pubmed Zimmermann,
Plasticity of the nervous system at the systematic, cellular and molecular levels: a mechanism of chronic pain and hyperalgesia.
1996,
Pubmed
